Close

MatTek and AIM Biotech Partner on Advanced 3D Tissue Culture Organ-on-a-Chip Systems

Paid press release content from Reportable. The StreetInsider.com news staff was not involved in its creation.

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/19/2024

1. LVS
2. TSM
3. SPY
4. NFLX
5. CSX
6. UAL
7. ALK
8. EFX
9. TSLA
10. INFY


June 1, 2023 9:10 AM EDT

Boston, MA - June 1, 2023 – Today, MatTek Life Sciences and AIM Biotech announced a strategic partnership through which the AIM Biotech portfolio will be available for sale through MatTek. Over the last thirty years, MatTek has become the leader in the advanced cell culture space and is continually working to broaden its portfolio of products and services. The partnership with AIM Biotech allows MatTek to provide an ever more comprehensive suite of products and services to its clients and customers. This includes the innovative organiX™ and idenTx™ microfluidic 3D tissue culture platforms as well as comprehensive drug discovery research services in key therapeutic areas of immuno-oncology, vascular biology, and neurobiology.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • The partnership with AIM Biotech allows MatTek to provide an ever more comprehensive suite of products and services to its clients and customers.
  • As researchers push the envelope on advanced in vitro systems, they are becoming more interested in models which incorporate even more physiologically relevant features, such as perfusable vasculature, and even combining multiple organ systems.
  • The innovative organiX™ and idenTx™ microfluidic 3D tissue culture platforms enable such advanced models for companies developing innovative new treatments.

AIM Biotech is a biotechnology company at the forefront of transforming drug discovery into a more targeted, predictable and less expensive endeavor. The company’s patented microfluidic devices and humanized functional assays in critical therapeutic areas enable the addition of human data into drug development earlier in the process, enabling therapeutic insights not previously possible through conventional approaches. AIM Biotech is located in Singapore and Boston, MA.

Founded in 1985, MatTek Life Sciences began producing three-dimensional human tissue models as reliable replacements for animal testing. MatTek’s physiologically advanced tissue models empower companies in the cosmetics, chemical, and pharmaceutical industries to achieve their goals of non-animal testing while lowering preclinical costs and providing human-relevant results. With locations in the US and Europe, today MatTek’s offerings include skin, eye, oral, respiratory, vaginal, and intestinal tissue models including disease modeling, validated, and custom testing services, multiple donor primary cells, culture media, and highly optical culture ware.

Contacts:

Media & Investors
[email protected]

Scientific Inquiries
[email protected]

Source: AIM Biotech

Distributed by: Reportable, Inc.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Press Releases, Reportable